Mounjaro

Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga

Mounjaro Recent News

Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years.
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry.
Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies
Tesla, relegated from seventh to ninth on the mega-cap leaderboard, can give way to other companies that are more 'magnificent.'
Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound.
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.
Tesla's Market Cap Dips Below Eli Lilly Following Q4 Revenue Miss
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes, including Novo Nordisk's Ozempic.
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy.
Eli Lilly To Fly Higher? Fund Manager Gary Black Envisions Blockbuster Potential For Diabetes Drug Mounjaro
Lilly stock has been on a tear this year, thanks to the huge potential its GLP-1 agonist Mounjaro promises.
Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'
After This Pharma Stock Surges To Record High, Cramer Says It's 'Going Higher Still'
Eli Lilly reported a beat-and-raise Q2 on Tuesday and its stock moving into record territory and Cramer thinks there is more upside to it.
140,000 American Lives At Risk -- And This Drug Could Save Them
A new study could save hundreds of thousands of lives in the United States each year.
'Miracle' Weightloss Drugs Ozempic And Mounjaro Face Lawsuit Over Alleged Gastroparesis Side Effect
Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic And Mounjaro: WSJ
This New Drug May Be Even Stronger Than Ozempic For Weight Loss, Clinical Trial Shows - BI
Key Data On Novo Nordisk's Weight Loss Drug Wegovy Due In July: Biotech Analyst Details Likely Impact On Lilly's Stock
Want To Lose 10 Pounds? 'Miracle' Weight Loss Drugs Create Winners And Losers
Ozempic, Wegovy and Mounjaro could very well have become the most sought-after weight-loss drugs of the past two years, as press reports and social media amplification help push these new medications as a new "miracle treatment" for weight management. A February analysis by Jefferies puts sales of GLP-1 drugs for obesity above $100 billion by 2031.